PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism

Tadao Akizawa, Noriaki Kurita, Masahide Mizobuchi, Masafumi Fukagawa, Yoshihiro Onishi, Takuhiro Yamaguchi, Alan R. Ellis, Shingo Fukuma, M. Alan Brookhart, Takeshi Hasegawa, Kiyoshi Kurokawa, Shunichi Fukuhara

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)

Abstract

Cinacalcet lowers parathyroid hormone levels. Whether it can prolong survival of people with chronic kidney disease (CKD) complicated by secondary hyperparathyroidism (SHPT) remains controversial, in part because a recent randomized trial excluded patients with iPTH <300 pg/ml. We examined cinacalcet's effects at different iPTH levels. This was a prospective case-cohort and cohort study involving 8229 patients with CKD stage 5D requiring maintenance hemodialysis who had SHPT. We studied relationships between cinacalcet initiation and important clinical outcomes. To avoid confounding by treatment selection, we used marginal structural models, adjusting for time-dependent confounders. Over a mean of 33 months, cinacalcet was more effective in patients with more severe SHPT. In patients with iPTH ≥500 pg/ml, the reduction in the risk of death from any cause was about 50% (Incidence Rate Ratio [IRR] = 0.49; 95% Confidence Interval [95% CI]: 0.29-0.82). For a composite of cardiovascular hospitalization and mortality, the association was not statistically significant, but the IRR was 0.67 (95% CI: 0.43-1.06). These findings indicate that decisions about using cinacalcet should take into account the severity of SHPT.

Original languageEnglish
Article number19612
JournalScientific reports
Volume6
DOIs
Publication statusPublished - 2016 Apr 13
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism'. Together they form a unique fingerprint.

Cite this